Icom Incorporated

The General Hospital Corporation

Mitsui Chemicals, Inc.

Hiroshi Kawasaki

Yuma Oda

Akihiro Imai

Mikio Matsufuji

Kenneth Tanabe

Yoshiaki Miyakoshi

Bryan C Fuchs

Kazuaki Imamura

Taiji Morimoto

A gateway device () relays voice communication between a communication terminal to be connected to a closed network () and a communication terminal to be connected to a LAN (). The gateway device () includes a closed network communicator () connected to the closed network (), a communication relay () to perform encapsulation or decapsulation of data for enabling voice communication between the closed network () and the LAN (), and a LAN communicator () connected to the LAN ().

Wireless system, relay method, and communication terminal

A communication control device includes an association table updater and a correction packet transmitter. The association table updater updates, when receiving from a first wireless device a packet containing an identification number of a first communication terminal connected to the first wireless device, an association table storing an address of the first wireless device and the identification number of the first communication terminal. The correction packet transmitter transmits, when a packet received from a second wireless device to which a second communication terminal is connected contains an address of the second wireless device, an identification number of the second communication terminal, and an identification number indicating a destination of the packet, and when the identification number indicating the destination is the identification number of the first communication terminal stored in the association table, a correction packet containing the address of the second wireless device and the identification number of the second communication terminal to the first wireless device after the packet is transmitted to the first wireless device.

Communication control device, wireless device, communication control system, communication control method and program

A two-component curable solventless adhesive which enables a laminated composite film comprising a barrier layer and a plastic film laminated with each other to maintain excellent appearance and adhesive strength for a long period even after a sterilization treatment at high temperature, and to appropriately adjust a reaction between a base resin and a curing agent during a production of the laminated composite film. The two-component curable solventless adhesive comprises a base resin and a curing agent, wherein the base resin contains a polyol having an acid group and a secondary or tertiary terminal hydroxyl group accounting for 30% or more of the entire terminal hydroxyl groups of the polyol, and the curing agent contains an isocyanate group-terminated urethane prepolymer containing at least an aralkyl polyisocyanate and/or a modified substance thereof as a raw polyisocyanate, and a content of a low molecular weight polyisocyanate is defined.

Two-component curable solventless adhesive

The present invention relates to diagnostic and prognostic methods to determine the likelihood of a subject who has a inflammatory disease or liver disease of developing cancer. In particular, the present invention relates to methods for identifying subjects with increased susceptibility to developing cancer, such as hepatocellular carcinoma (HCC) where the subject has an inflammatory disease, such as, but not limited to cirrhosis, by identifying a variance or polymorphism in the human EGF gene. In particular, the methods of the present invention relate to identifying subjects with increased susceptibility to developing cancer such as HCC, where the subject has an inflammatory disease, such as but not limited to cirrhosis, and the subject is identified to have a single nucleotide polymorphism 61A&#x3e;G in the 5'UTR of the EGF gene. Alternatively, the methods of the present invention relate to identifying subjects with increased susceptibility to developing cancer such as HCC, where the subject has an inflammatory disease, such as but not limited to cirrhosis, and the subject is identified to have increased expression of EGF as compared to a reference level of EGF expression. The present invention also relates to administering an effective amount of an anti-cancer therapy to subjects identified to have an increased susceptibility of developing cancer such as HCC by the methods as disclosed herein, and kits to identify a subject with a 61A&#x3e;G polymorphism in the 5&#x2032;UTR of the EGF gene or kits to determine increased EGF expression in subjects with chronic inflammatory disease.

Epidermal growth factor (EGF) expression and/or polymorphisms thereof for predicting the risk of developing cancer

Growing community of inventors

Osaka, Japan

Hiroshi Kawasaki